Medfiles participating in significant Horizon 2020 funding for testing cell therapy in stroke patients
For the first time in the world, a research project funded by the EU will explore the efficacy of cell therapy in stroke patients. Medfiles Ltd, the University of Eastern Finland and the University of Tampere are involved in the RESSTORE consortium that has been awarded 6.3 million euros of Horizon 2020 funding to study adipose tissue derived mesenchymal stem cells in stroke patients.
Cerebrovascular disorders are the main cause of adult disability. Unfortunately, effective therapies have not been found to promote stroke recovery. Cell therapies are a promising approach to improve functional recovery after stroke.
The funded RESSTORE project is exceptional in many ways. Altogether 400 patients will be recruited, half of whom will receive a cell preparation. The therapeutic efficacy will be assessed and monitored in patients using clinical rating scales, novel blood biomarkers and multimodal MRI. The project is an international multi-centre study with partners from Spain, England, France and the Czech Republic. In Finland, patients will be treated in Kuopio and Tampere University Hospitals. Medfiles Ltd is responsible for the study centres' coordination, monitoring and data management. The required cell number is high and thus the cells will be produced by four European centres, one of which is the University of Tampere (Regea Cell and Tissue Center).
The project is also special due to it involving experimental research. Complementary ancillary animal studies support the clinical trial by defining the impact of rehabilitation and co-morbid conditions, such as high blood pressure and diabetes.
The granted funding for the Finnish partners is significant and a recognition of the long-term scientific work from experimental research to patient care and clinical trials.
For further details, please contact CEO Tuija Keinonen, email@example.com